Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07176910
Recruiting Not applicable

Doppler Ultrasound-Guided Angiopuncture for Dysmenorrhea Pain: A Clinical Trial

NCT07176910 · tracked via the Priya Life Science China tracker
Sponsor
City University of Hong Kong
Phase
Not applicable
Started
2024-09-01
Last updated
2025-09-16

Condition(s) studied

AngiopunctureDysmenorrheaDopplar Ultrasound

Investigational drug(s) / intervention(s)

conduct angiopuncture on perforator points

conduct angiopuncture on perforator points: conducted angiopuncutre on patients of intervention group, and compare those patients pain scores before and after angiopuncture therapy.

Study summary

the study is to evaluated dopplar guided angiopuncture efficacy and safety in patients with dysmenorrhea

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: Primary dysmenorrhea diagnosis (≥6 months of menstrual pain scoring ≥2 on numerical rating scale) Regular menstrual cycles (28-32 days), menstrual period lasts 4 to 7 days No pelvic pathology on transvaginal ultrasound. Exclusion Criteria: coagulopathy (INR \>1.5) recent analgesic use (48-hour washout) secondary dysmenorrhea confirmed by laparoscopy.

Primary outcome measure(s)

  • visual analog scale — pre-treatment, immediate post-treatment, check up 1, check up 2, check up 3 (3 check ups lasts for 3 months post therapy, with each for 1 month)
    to measure pain score before and after angiopuncture

Trial sites (1)

FacilityCityRegionStatus
The Third Affiliated Hospital of Changchun University of Chinese Medicine Changchun China Recruiting

More City University of Hong Kong trials in China

Jockey Club Support Project Recruiting
We-INtervention Among Chinese HIV-serodiscordant Male Couples Recruiting
Online Self-healing Program Starting soon

Other trials for the same condition

The Impact of Oral Probiotics on Improving the Quality of Life in Patients With Dysmenorrhea. Active, not recruiting
Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07176910 on ClinicalTrials.gov ↗ ← All trials in China